Susan L. Hills
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Susan L. Hills has a total of 250 co-authors. Here are the top co-authors by number of shared publications:
Marc Fischer
Centers for Disease Control and Prevention, Fort Collins, USA
17 shared publicationsBrad J. Biggerstaff
Division of Vector-Borne Diseases, Centers for Disease Control and Prevention, Fort Collins, Colorado, USA
5 shared publicationsJ. Erin Staples
Arboviral Diseases Branch, Centers for Disease Control and Prevention, Fort Collins, USA
5 shared publicationsJaneen Laven
Division of Vector-Borne Diseases, Centers for Disease Control and Prevention, Fort Collins, Colorado, USA
4 shared publicationsSann Chan Soeung
National Immunization Program, Ministry of Health, Phnom Penh, Cambodia
4 shared publicationsOlga Kosoy
Division of Vector-Borne Diseases, Centers for Disease Control and Prevention, Fort Collins, Colorado, USA
3 shared publications
Latest Publications
- Open Access
- 4 September 2026
- Published by Springer Nature in npj Vaccines
High seroprotection rates among adults 10 years after inactivated Vero cell-derived Japanese encephalitis vaccine, IXIARO
Japanese encephalitis (JE), a mosquito-borne, vaccine-preventable disease, is a risk in parts of Asia and Oceania. A previous study showed that after a primary 2-dose series and booster dose of the Vero cell-derived JE vaccine (JE-VC; IXIARO), high seroprotection rates in adults persisted through 6 years. We used serum samples from U.S. military personnel aged 29–55 years to investigate seroprotection at 10 years after the booster dose (based on a 50% plaque reduction neutralization test titer of ≥10). Overall, 97% (95% confidence interval [CI]: 94–98%) of 300 individuals were seroprotected at approximately 10 years with a geometric mean titer of 165 (95% CI: 140–195). Neutralizing antibody titers were not significantly associated with age, intervals between primary series or booster doses, or previous yellow fever vaccination. Young and middle-aged adults who have completed a JE-VC primary series and booster maintain high seroprotection rates for at least 10 years.
- 4 September 2026
- Published by Springer Nature in npj Vaccines
Open AccessHigh seroprotection rates among adults 10 years after inactivated Vero cell-derived Japanese encephalitis vaccine, IXIARO
Japanese encephalitis (JE), a mosquito-borne, vaccine-preventable disease, is a risk in parts of Asia and Oceania. A previous study showed that after a primary 2-dose series and booster dose of the Vero cell-derived JE vaccine (JE-VC; IXIARO), high seroprotection rates in adults persisted through 6 years. We used serum samples from U.S. military personnel aged 29–55 years to investigate seroprotection at 10 years after the booster dose (based on a 50% plaque reduction neutralization test titer of ≥10). Overall, 97% (95% confidence interval [CI]: 94–98%) of 300 individuals were seroprotected at approximately 10 years with a geometric mean titer of 165 (95% CI: 140–195). Neutralizing antibody titers were not significantly associated with age, intervals between primary series or booster doses, or previous yellow fever vaccination. Young and middle-aged adults who have completed a JE-VC primary series and booster maintain high seroprotection rates for at least 10 years.
- Open Access
- 18 August 2026
- Published by Public Library of Science (PLoS) in PLOS Neglected Tropical Diseases
- Vol. 20 (8) , e0014641
Japanese encephalitis: Current status, recent progress, and persistent challenges
Japanese encephalitis (JE), a mosquito‑borne, vaccine‑preventable disease, is endemic to much of Asia and parts of Oceania. Its main clinical manifestation, encephalitis, is associated with a 20–30% case-fatality rate and long-term sequelae in 30%–50% of survivors. During the past two decades, substantial progress has been made in JE prevention and control. Notably, several countries have introduced JE vaccine into their national immunization programs, leading to marked reductions in morbidity and mortality. Nonetheless, major challenges remain, particularly because the disease cannot be eradicated meaning high-quality, long-term JE vaccination programs must be maintained. In addition, JEV has emerged in an increasingly wide geographic area, including in widespread parts of Australia, and shifts in the age distribution of cases towards adults in some JE-endemic areas have occurred. In this review, we summarize current knowledge on JE, outline recent advances in prevention and control, and describe key persisting and emerging concerns. Addressing these issues and continuing efforts to strengthen JE immunization programs will be important to reducing the burden of this disease for populations in endemic areas now and in the future.
- 18 August 2026
- Published by Public Library of Science (PLoS) in PLOS Neglected Tropical Diseases
- Vol. 20 (8) , e0014641
Open AccessJapanese encephalitis: Current status, recent progress, and persistent challenges
Japanese encephalitis (JE), a mosquito‑borne, vaccine‑preventable disease, is endemic to much of Asia and parts of Oceania. Its main clinical manifestation, encephalitis, is associated with a 20–30% case-fatality rate and long-term sequelae in 30%–50% of survivors. During the past two decades, substantial progress has been made in JE prevention and control. Notably, several countries have introduced JE vaccine into their national immunization programs, leading to marked reductions in morbidity and mortality. Nonetheless, major challenges remain, particularly because the disease cannot be eradicated meaning high-quality, long-term JE vaccination programs must be maintained. In addition, JEV has emerged in an increasingly wide geographic area, including in widespread parts of Australia, and shifts in the age distribution of cases towards adults in some JE-endemic areas have occurred. In this review, we summarize current knowledge on JE, outline recent advances in prevention and control, and describe key persisting and emerging concerns. Addressing these issues and continuing efforts to strengthen JE immunization programs will be important to reducing the burden of this disease for populations in endemic areas now and in the future.
- Open Access
- 14 August 2025
- Published by European Centre for Disease Control and Prevention (ECDC) in Eurosurveillance
- Vol. 30 (32)
Surveillance for adverse events following use of live attenuated chikungunya vaccine, United States, 2024, and the associated public health response in 2024 and 2025
A live attenuated chikungunya vaccine (IXCHIQ) received licensure in the United States (US) for ≥ 18-year-olds in November 2023. Post-licensure safety surveillance identified 28 adverse events in 2024 among US persons, including six neurological or cardiac serious adverse events (SAEs) in males ≥ 65 years. In early 2025, providers were alerted, a precaution for older persons was issued and vaccine guidance was updated. In May, following 11 additional SAEs reported outside the US, use in older persons was temporarily paused until 6 August 2025.
- 14 August 2025
- Published by European Centre for Disease Control and Prevention (ECDC) in Eurosurveillance
- Vol. 30 (32)
Open AccessSurveillance for adverse events following use of live attenuated chikungunya vaccine, United States, 2024, and the associated public health response in 2024 and 2025
A live attenuated chikungunya vaccine (IXCHIQ) received licensure in the United States (US) for ≥ 18-year-olds in November 2023. Post-licensure safety surveillance identified 28 adverse events in 2024 among US persons, including six neurological or cardiac serious adverse events (SAEs) in males ≥ 65 years. In early 2025, providers were alerted, a precaution for older persons was issued and vaccine guidance was updated. In May, following 11 additional SAEs reported outside the US, use in older persons was temporarily paused until 6 August 2025.
- Top Cited PapersOpen Access
- 11 February 2025
- Published by American Society of Tropical Medicine and Hygiene in The American Journal of Tropical Medicine and Hygiene
- Vol. 112 (5) , 1026-1035
A Review of the Recent Epidemiology of Zika Virus Infection
Zika virus (ZIKV) is a flavivirus transmitted primarily by the bite of infected Aedes species mosquitoes. Although typically asymptomatic or causing mild symptoms and infrequent neurological disease in older children and adults, infection during pregnancy can result in severe congenital malformations and neurodevelopmental deficits. We conducted a review of published literature and official data sources to describe recent Zika epidemiological trends, building on WHO updates posted in 2019 and 2022. Globally, cases declined after the height of ZIKV transmission in the Americas in 2015–2016; however, transmission continues across multiple regions, with intermittent outbreaks reported. As of December 2023, there is documented evidence of current or prior autochthonous mosquito-borne ZIKV transmission in 92 countries and territories; most recently, Guinea, Mali, and Sri Lanka were included on the basis of recent or retrospective testing of specimens collected during surveillance activities or studies. The abundance of asymptomatic and mild infections and limited diagnostic testing suggest that transmission in many locations likely remains underrecognized. Public health authorities, clinicians, communities at risk, and travelers should remain alert to the possibility of ZIKV transmission and implement measures to limit the risk of infection with ZIKV and other Aedes-borne arboviruses. To strengthen surveillance for ZIKV infections and congenital disease, targeted surveillance using clear case definitions and epidemiologically appropriate laboratory testing algorithms should be applied.
- 11 February 2025
- Published by American Society of Tropical Medicine and Hygiene in The American Journal of Tropical Medicine and Hygiene
- Vol. 112 (5) , 1026-1035
Top Cited PapersOpen AccessA Review of the Recent Epidemiology of Zika Virus Infection
Zika virus (ZIKV) is a flavivirus transmitted primarily by the bite of infected Aedes species mosquitoes. Although typically asymptomatic or causing mild symptoms and infrequent neurological disease in older children and adults, infection during pregnancy can result in severe congenital malformations and neurodevelopmental deficits. We conducted a review of published literature and official data sources to describe recent Zika epidemiological trends, building on WHO updates posted in 2019 and 2022. Globally, cases declined after the height of ZIKV transmission in the Americas in 2015–2016; however, transmission continues across multiple regions, with intermittent outbreaks reported. As of December 2023, there is documented evidence of current or prior autochthonous mosquito-borne ZIKV transmission in 92 countries and territories; most recently, Guinea, Mali, and Sri Lanka were included on the basis of recent or retrospective testing of specimens collected during surveillance activities or studies. The abundance of asymptomatic and mild infections and limited diagnostic testing suggest that transmission in many locations likely remains underrecognized. Public health authorities, clinicians, communities at risk, and travelers should remain alert to the possibility of ZIKV transmission and implement measures to limit the risk of infection with ZIKV and other Aedes-borne arboviruses. To strengthen surveillance for ZIKV infections and congenital disease, targeted surveillance using clear case definitions and epidemiologically appropriate laboratory testing algorithms should be applied.
- 4 September 2024
- Published by American Society of Tropical Medicine and Hygiene in The American Journal of Tropical Medicine and Hygiene
- Vol. 111 (3) , 598-602
Colorado Tick Fever in the United States, 2013–2022
: Colorado tick fever (CTF) virus is an arbovirus maintained in an enzootic cycle between Rocky Mountain wood ticks (Dermacentor andersoni) and rodent species in the western United States. Individuals with CTF typically present with symptoms including fever, headache, myalgia, and lethargy, with a biphasic illness frequently occurring. We reviewed data on CTF cases reported to the national U.S. arboviral disease surveillance system and identified through testing at the CDC to characterize the epidemiology of CTF from 2013–2022. During this period, 148 CTF cases were identified, all likely infected in an endemic area in one of six states (Montana, Wyoming, Oregon, Colorado, Utah, Idaho). A median of 11 cases (range: 5–37) were identified per year, with an average annual national incidence of 0.04 cases per million population. The median age of cases was 55 years (range: 1–84 years), and 96 (65%) were male. Most (n = 145; 98%) cases acquired infection from April through July. The hospitalization rate was 16% (16 of 102 cases with data), and no deaths were reported. These findings substantiate the continued circulation of CTF virus in the western United States, highlighting the importance of implementing approaches to ensure CTF awareness for medical providers and providing education on tick bite prevention strategies for residents and visitors to risk areas.
- 4 September 2024
- Published by American Society of Tropical Medicine and Hygiene in The American Journal of Tropical Medicine and Hygiene
- Vol. 111 (3) , 598-602
Colorado Tick Fever in the United States, 2013–2022
: Colorado tick fever (CTF) virus is an arbovirus maintained in an enzootic cycle between Rocky Mountain wood ticks (Dermacentor andersoni) and rodent species in the western United States. Individuals with CTF typically present with symptoms including fever, headache, myalgia, and lethargy, with a biphasic illness frequently occurring. We reviewed data on CTF cases reported to the national U.S. arboviral disease surveillance system and identified through testing at the CDC to characterize the epidemiology of CTF from 2013–2022. During this period, 148 CTF cases were identified, all likely infected in an endemic area in one of six states (Montana, Wyoming, Oregon, Colorado, Utah, Idaho). A median of 11 cases (range: 5–37) were identified per year, with an average annual national incidence of 0.04 cases per million population. The median age of cases was 55 years (range: 1–84 years), and 96 (65%) were male. Most (n = 145; 98%) cases acquired infection from April through July. The hospitalization rate was 16% (16 of 102 cases with data), and no deaths were reported. These findings substantiate the continued circulation of CTF virus in the western United States, highlighting the importance of implementing approaches to ensure CTF awareness for medical providers and providing education on tick bite prevention strategies for residents and visitors to risk areas.
- Open Access
- 10 November 2023
- Published by Centers for Disease Control MMWR Office in MMWR. Recommendations and Reports
- Vol. 72 (5) , 1-29
Tick-Borne Encephalitis Vaccine: Recommendations of the Advisory Committee on Immunization Practices, United States, 2023
ACIP recommendations for use of the TBE vaccine among U.S. travelers and laboratory workers.
- 10 November 2023
- Published by Centers for Disease Control MMWR Office in MMWR. Recommendations and Reports
- Vol. 72 (5) , 1-29
Open AccessTick-Borne Encephalitis Vaccine: Recommendations of the Advisory Committee on Immunization Practices, United States, 2023
ACIP recommendations for use of the TBE vaccine among U.S. travelers and laboratory workers.
- Open Access
- 28 July 2023
- Published by Elsevier in Travel Medicine and Infectious Disease
- Vol. 55, 102624
Arboviral vaccines for use in pregnant travelers
- 28 July 2023
- Published by Elsevier in Travel Medicine and Infectious Disease
- Vol. 55, 102624
Open AccessArboviral vaccines for use in pregnant travelers
- Open Access
- 9 June 2023
- Published by Centers for Disease Control MMWR Office in MMWR. Morbidity and Mortality Weekly Report
- Vol. 72 (23) , 636-638
Notes from the Field: Chikungunya Outbreak — Paraguay, 2022–2023
This report describes an outbreak of chikungunya virus transmitted by mosquitoes in Paraguay.
- 9 June 2023
- Published by Centers for Disease Control MMWR Office in MMWR. Morbidity and Mortality Weekly Report
- Vol. 72 (23) , 636-638
Open AccessNotes from the Field: Chikungunya Outbreak — Paraguay, 2022–2023
This report describes an outbreak of chikungunya virus transmitted by mosquitoes in Paraguay.
- Open Access
- 3 May 2023
- Published by American Society of Tropical Medicine and Hygiene in The American Journal of Tropical Medicine and Hygiene
- Vol. 108 (5) , 860-864
Japanese Encephalitis among Adults: A Review
: Japanese encephalitis (JE) is becoming an increasingly important issue among adults. The reasons for this are multifactorial. During the past decades, new areas of Japanese encephalitis virus (JEV) transmission have occurred in several locations, most notably in a markedly expanded area of Australia during 2021–2022. When JEV enters new areas, cases in adults frequently occur. This is unlike the typical pattern in endemic areas where the burden of disease is in children because most adults are protected through natural immunity following earlier exposure to the virus. Even in endemic areas, JEV has become relatively more important in adults because improved JE control through childhood immunization programs has resulted in a substantial decrease in pediatric JE cases and thus more prominence of adult JE cases. Finally, increases in tourism to JE risk areas have resulted in more exposure of adult travelers, who are usually non-immune, to infection in JE risk areas. In this review we describe the increasing importance of JE in adults in some areas and then consider the comparative clinical presentation and severity of illness among children and adults.
- 3 May 2023
- Published by American Society of Tropical Medicine and Hygiene in The American Journal of Tropical Medicine and Hygiene
- Vol. 108 (5) , 860-864
Open AccessJapanese Encephalitis among Adults: A Review
: Japanese encephalitis (JE) is becoming an increasingly important issue among adults. The reasons for this are multifactorial. During the past decades, new areas of Japanese encephalitis virus (JEV) transmission have occurred in several locations, most notably in a markedly expanded area of Australia during 2021–2022. When JEV enters new areas, cases in adults frequently occur. This is unlike the typical pattern in endemic areas where the burden of disease is in children because most adults are protected through natural immunity following earlier exposure to the virus. Even in endemic areas, JEV has become relatively more important in adults because improved JE control through childhood immunization programs has resulted in a substantial decrease in pediatric JE cases and thus more prominence of adult JE cases. Finally, increases in tourism to JE risk areas have resulted in more exposure of adult travelers, who are usually non-immune, to infection in JE risk areas. In this review we describe the increasing importance of JE in adults in some areas and then consider the comparative clinical presentation and severity of illness among children and adults.